Goldline Pharmaceutical Limited
CIN.: L51397MH2004PLC147806

To
The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai - 400001.

Date: 05/11/2026

Scrip Code: 544759, Scrip ID: GLPL,

Subject: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to be held on **Saturday, November 14, 2026**.

Dear Sir / Ma'am,

Pursuant to Regulation 29 (1) (a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended **('SEBI Listing Regulations'),** we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on **Saturday, November 14, 2026,** at the Registered Office of the Company at 103, F-1, Leela Apartment, Shilpa Hsg Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, India, 440015, inter-alia, to transact the following businesses:

Financial Results for half year ended 30th September, 2026:

1. The Standalone Unaudited Financial Results set out in compliance with applicable Accounting Standards for the half-year ended 30th September, 2026, together with Statement of Assets and Liabilities.

Further, the outcome of the aforesaid meeting shall be filed separately.

Kindly take this intimation on your record.

Yours faithfully,

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi

Digitally signed by Ruchi Sanket Modi
Date: 2026.11.05 17:08:48 +05'30'

Ruchi Sanket Modi
Company Secretary cum Compliance Officer